摘要
目的探讨同型半胱氨酸(Hcy)水平对视网膜静脉阻塞(RVO)继发黄斑水肿(ME)程度的影响。方法选取2021年2月至2022年12月收治的80例经过眼科检测确诊及纳排标准筛选后的RVO继发ME患者设为观察组;另选取80例健康体检者无眼科疾病患者作为对照组,对比2组患者一般资料并检测Hcy水平,分析黄斑水肿程度与Hcy相关性。结果观察组患者Hcy水平显著高于对照组(P<0.05)。不同视网膜静脉阻塞黄斑水肿程度组患者的Hcy水平对比结果:轻度、中度和重度患者血浆VEGF、Hcy水平差异有统计学意义(P<0.05);中度组Hcy水平高于轻度组(P<0.05),重度组Hcy水平高于轻度组与中度组(P<0.05)。以血浆Hcy为自变量,以水肿程度作为因变量,Logistic回归分析显示血浆Hcy水平是视网膜静脉阻塞黄斑水肿程度的独立危险因素。结论血浆Hcy与RVO继发ME的程度具有相关性,Hcy水平升高,患者视网膜静脉阻塞黄斑水肿程度就增加,导致病情进展,应用降低Hcy药物可对RVO继发ME进行预防与治疗。
Objective To investigate the effect of homocysteine(Hcy)levels on the degree of macular edema(ME)secondary to retinal vein occlusion(RVO).Methods A total of 80 patients with ME secondary to RVO who were confirmed by ophthalmic examination and screened by the inclusion and exclusion criteria in our hospital from February 2021 to December 2022 were selected as the observation group.Another 80 healthy subjects without eye diseases,who received physical examination during the same period were selected as the control group.General data of the two groups were compared.Hcy levels were detected to analyze the correlation with the degree of ME.Results Hcy level in the observation group was significantly higher than that of control group(P<0.05).Hcy levels in patients with different degrees of ME secondary to RVO were compared.There were significant differences in plasma vascular endothelial growth factor(VEGF)and Hcy levels in mild,moderate and severe patients(P<0.05).The level of Hcy in the moderate group was significantly higher than that of the mild group(P<0.05),which,in the severe group was significantly higher than that of the mild and moderate groups(P<0.05).With plasma Hcy as an independent variable and edema degree as a dependent variable,Logistic regression analysis showed that plasma Hcy level was an independent risk factor for ME secondary to RVO.Conclusion Plasma Hcy is correlated with the degree of ME secondary to RVO.With the increase in Hcy level,the degree of ME in RVO patients increases,leading to the disease progression.The application of Hcy lowering drugs can be used for the prevention and treatment of ME secondary to RVO.
作者
何敬
马楠
霍红
范红芳
侯丽萍
张洁
韩春彦
王淑珍
HE Jing;MA Nan;HUO Hong(Department of Ophthalmology,Zhangjiakou First Hospital,Hebei,Zhangjiakou 075000,China)
出处
《河北医药》
CAS
2023年第21期3304-3306,共3页
Hebei Medical Journal
基金
河北省医学科学研究课题计划(编号:20221884)。